Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

被引:245
作者
Abe, M
Hiura, K
Wilde, J
Shioyasono, A
Moriyama, K
Hashimoto, T
Kido, S
Oshima, T
Shibata, H
Ozaki, S
Inoue, D
Matsumoto, T
机构
[1] Univ Tokushima, Dept Med & Bioregulatory Sci, Grad Sch Med, Tokushima 7708503, Japan
[2] Univ Tokushima, Sch Dent, Dept Orthodont, Tokushima 7708503, Japan
[3] Univ Tokushima Hosp, Div Transfus Med, Tokushima 7708503, Japan
关键词
D O I
10.1182/blood-2003-11-3839
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple myeloma (MM) expands in the bone marrow and causes devastating bone destruction by enhancing osteoclastic bone resorption in its vicinity, suggesting a close interaction between MM cells and osteoclasts (OCs). Here, we show that peripheral blood mononuclear cell-derived OCs enhanced growth and survival of primary MM cells as well as MM cell lines more potently than stromal cells, and that OCs protected MM cells from apoptosis induced by serum depletion or doxorubicin. OCs produced osteopontin (OPN) and interleukin 6 (IL-6), and adhesion of MM cells to OCs increased IL-6 production from OCs. In addition, IL-6 and OPN in combination enhanced MM cell growth and survival. However, the effects of OCs on MM cell growth and survival were only partially suppressed by a simultaneous addition of anti-IL-6 and anti-OPN antibodies and were completely abrogated by inhibition of cellular contact between MM cells and OCs. These results demonstrate that OCs enhance MM cell growth and survival through a cell-cell contact-mediated mechanism that is partially dependent on IL-6 and OPN. It is suggested that interactions of MM cells with OCs augment MM growth and survival and, thereby, form a vicious cycle, leading to extensive bone destruction and MM cell expansion. (C) 2004 by The American Society of Hematology.
引用
收藏
页码:2484 / 2491
页数:8
相关论文
共 52 条
  • [1] Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma
    Abe, M
    Hiura, K
    Wilde, J
    Moriyama, K
    Hashimoto, T
    Ozaki, S
    Wakatsuki, S
    Kosaka, M
    Kido, S
    Inoue, D
    Matsumoto, T
    [J]. BLOOD, 2002, 100 (06) : 2195 - 2202
  • [2] Abe M, 1998, CLIN EXP IMMUNOL, V111, P457
  • [3] Anderson Kenneth C, 2002, Hematology Am Soc Hematol Educ Program, P214
  • [4] [Anonymous], J CLIN ONCOL
  • [5] Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity
    Ashkar, S
    Weber, GF
    Panoutsakopoulou, V
    Sanchirico, ME
    Jansson, M
    Zawaideh, S
    Rittling, SR
    Denhardt, DT
    Glimcher, MJ
    Cantor, H
    [J]. SCIENCE, 2000, 287 (5454) : 860 - 864
  • [6] Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone
    Asou, Y
    Rittling, SR
    Yoshitake, H
    Tsuji, K
    Shinomiya, K
    Nifuji, A
    Denhardt, DT
    Noda, M
    [J]. ENDOCRINOLOGY, 2001, 142 (03) : 1325 - 1332
  • [7] Multiple myeloma
    Bataille, R
    Harousseau, JL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (23) : 1657 - 1664
  • [8] Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression
    Chellaiah, MA
    Kizer, N
    Biswas, R
    Alvarez, U
    Strauss-Schoenberger, J
    Rifas, L
    Rittling, SR
    Denhardt, DT
    Hruska, KA
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2003, 14 (01) : 173 - 189
  • [9] AYL-1A and AML-1B regulation of MIP-1α expression in multiple myeloma
    Choi, SJ
    Oba, T
    Callander, NS
    Jelinek, DF
    Roodman, GD
    [J]. BLOOD, 2003, 101 (10) : 3778 - 3783
  • [10] Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease
    Choi, SJ
    Oba, Y
    Gazitt, Y
    Alsina, M
    Cruz, J
    Anderson, J
    Roodman, GD
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (12) : 1833 - 1841